MedPath

Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study)

Not Applicable
Completed
Conditions
Mild-to-moderate Ulcerative Colitis
Interventions
Other: PRO-2 Scoring
Other: Faecal Calprotectin Home Test
Registration Number
NCT04340895
Lead Sponsor
Ferring Pharmaceuticals
Brief Summary

The purpose of this study is to provide evidence that a therapy of Ulcerative Colitis (UC) disease adjusted on tight monitoring of non-invasive parameters, such as clinical symptoms and faecal calprotectin (FC) (substance that is released when intestines are inflamed and that can be measured in faeces), can provide significantly higher benefit for the participants in terms of disease control and quality of life (QoL) improvement, compared to a symptom-based approach only.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
250
Inclusion Criteria
  • Adult Participants (≥ 18 years old)
  • Participants with active mild-to-moderate UC (with RB and bowel inflammation confirmed by endoscopy)
  • Participants with treatment with 5-aminosalicylic acid (5-ASA) ≤ 2.4 g/day or with no treatment regimen at Baseline
  • Participants who agree to use FC home test (to dose FC in faeces as a marker of inflammation)
  • Participants with internet access and smartphone with camera
Exclusion Criteria
  • Participants currently enrolled in another interventional study
  • Participants not willing to undergo an endoscopy at the end of study
  • Participants with contraindications to treatment with 5-ASA and/or 2nd generation corticosteroids
  • Participants not willing to perform FC self-testing in faeces at home

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Reference armPRO-2 ScoringTreatment optimization (escalation/de-escalation) performed by the investigator based on clinical symptoms (PRO-2 scoring) only. The PRO-2 scoring will be assessed during clinic visits every 3-months during active disease, every 6 months during remission, or when a participant feels the need; as per recommended standard practice.
Intervention armFaecal Calprotectin Home TestTreatment optimization (escalation/de-escalation) performed by the investigator based on participant self-monitoring of FC values and/or clinical symptoms (patient-reported outcome-2 \[PRO-2\] scoring). The FC Test and/or PRO-2 scoring will be done by the participant at home every month during active disease, every 3 months in remission, or when a participant feels the need/presents clinical symptoms.
Intervention armPRO-2 ScoringTreatment optimization (escalation/de-escalation) performed by the investigator based on participant self-monitoring of FC values and/or clinical symptoms (patient-reported outcome-2 \[PRO-2\] scoring). The FC Test and/or PRO-2 scoring will be done by the participant at home every month during active disease, every 3 months in remission, or when a participant feels the need/presents clinical symptoms.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants with Mayo Endoscopic Sub-score = 0At 12 months

Defined as the percentage of participants achieved mucosal healing (Mayo endoscopic sub-score of 0 \[normal friability\]). The Mayo endoscopic scoring ranges from 0-3 with higher scores indicating greater disease severity. The score is defined as 0-3: 0= Normal; 1=Mild friability; 2 = Moderate friability; 3 = Exudation, spontaneous hemorrhage.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants with Stool Frequency <=1At 12 months

Defined as the percentage of participants with SF\<=1. The SF score ranges from 0-3 with higher scores indicating greater disease severity. The score was defined as 0-3: 0 = None; 1 = 1-2 stools/day \> normal; 2 = 3-4 stools/day \> normal; 3 = \>4 stools/day \> normal

Change in Work Productivity and Activity Impairment: Ulcerative Colitis (WPAI: UC) QuestionnaireFrom Baseline over 12 Months

The WPAI-UC is a questionnaire with 6 questions used to evaluate lost productivity (work time missed and work and activity impairment) during the past 7 days due to UC. The scores are presented as percentages.

Faecal Calprotectin Value Changes at the Defined Study Time Points (Interventional Arm Only)Over 12 months

The FC Test will be done by the participant at home every month during active disease, every 3 months in remission, or when participant feels the need/presents clinical symptoms.

Percentage of Participants with Mayo Endoscopic Sub-score <=1At 12 months

Defined as the percentage of participants achieved endoscopic remission (Mayo endoscopic sub-score \<=1 \[normal or mild friability\]). The Mayo endoscopic scoring ranges from 0-3 with higher scores indicating greater disease severity. The sub-score was defined as 0-3: 0 = Normal friability; 1 = Mild friability; 2 = Moderate friability; 3 = Exudation, spontaneous hemorrhage

Percentage of Participants Escalated to Rescue TherapyOver 12 months

Rescue therapy included systemic corticosteroids/ immunosuppressants /biologics.

Number of Ulcerative Colitis Related Procedures and/or SurgeriesOver 12 months

Number of UC related procedures and/or surgeries will be determined by UC related medical resources.

Percentage of Participants with Rectal Bleeding = 0At 12 months

Defined as the percentage of participants with no RB (RB=0). The RB score ranges from 0-3 with higher scores indicating greater disease severity. The score was defined as 0-3: 0 = None; 1 = Streak of blood; 2 = Obvious blood; 3 = Mostly blood

Change in Short Form Questionnaire-36 (SF-36)From Baseline over 12 Months

The SF-36 is a health-related survey that assesses participant's QoL and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental component score and physical component score). Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

Number of Outpatients Visits and Calls (Outside of Study Schedule)Over 12 months

Number of outpatients visits and calls (outside of study schedule) will be determined by UC related medical resources.

Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ)From Baseline over 12 Months

Defined as a change in the QoL using SIBDQ over 12 months. The SIBDQ consists of 10 questions, measuring systemic, social, Bowel, and emotional status; each question is scored on a scale from 1 (poor QoL) to 7 (optimum QoL). A higher score indicates a better QoL. Total scores range from 10 (poor QoL) to 70 (good QoL).

Number of Hospitalization DaysOver 12 months

Number of hospitalization days will be determined by UC related medical resources.

Trial Locations

Locations (42)

Ospedali Riuniti Villa Sofia-Cervello

🇮🇹

Palermo, Italy

University of Pecs

🇭🇺

Pécs, Hungary

EGK s.r.o. - Sanatorium sv. Anny

🇨🇿

Praha, Czechia

Vojenska nemocnice Brno p.o.

🇨🇿

Brno, Czechia

Hepato-Gastroenterologie HK, s.r.o.

🇨🇿

Hradec Králové, Czechia

Mediendo s.r.o.

🇨🇿

Praha, Czechia

ISCARE IVF a.s.

🇨🇿

Praha, Czechia

Bugat Pal Hospital

🇭🇺

Gyongyos, Hungary

Javorszky Odon Hospital

🇭🇺

Vac, Hungary

Semmelweis Egyetem, Isz. Sebeszeti es Intervencios Gasztroenterologiai Klinika

🇭🇺

Budapest, Hungary

Pannonia Mgánorvosi Centrum Kft

🇭🇺

Budapest, Hungary

Bacs-Kiskun Megyei Oktatokorhaz

🇭🇺

Kecskemet, Hungary

Jeroen Bosch Ziekenhuis

🇳🇱

Den Bosch, Netherlands

Szegedi Tudomnyegyetem

🇭🇺

Szeged, Hungary

KZ a.s. - Masaryk Hospital

🇨🇿

Usti nad Labem, Czechia

AOU Ospedali Riuniti di Ancona

🇮🇹

Ancona, Italy

Ospedale San Raffaele S.R.L

🇮🇹

Milano, Italy

ASST-FBF Luigi Sacco Hospital

🇮🇹

Milan, Italy

Azienda Ospedaliero - Universitaria Pisana

🇮🇹

Pisa, Italy

A.O.Città della salute e della scienza diTorino

🇮🇹

Torino, Italy

Catharina Ziekenhuis

🇳🇱

Eindhoven, Netherlands

Franciscus Gasthuis & Vlietland

🇳🇱

Rotterdam, Netherlands

NZOZ Vitamed

🇵🇱

Bydgoszcz, Poland

Szpital Uniwersytecki

🇵🇱

Bydgoszcz, Poland

Osrodek Sadan Klinicznych CLINSANTE

🇵🇱

Bydgoszcz, Poland

Centrum Medyczne LukaMed

🇵🇱

Chojnice, Poland

Karkonoskie Centrum Bada Klinicznych - Lexmedica SP Z O O

🇵🇱

Jelenia Góra, Poland

Centrum Medyczne Medyk

🇵🇱

Rzeszow, Poland

Centrum Medyczne Promed

🇵🇱

Krakow, Poland

Orodek Bada Klinicznych Allmedica

🇵🇱

Nowy Targ, Poland

H-T. Centrum Medyczne sp. z o.o.

🇵🇱

Tychy, Poland

Korczowski Bartosz, Gabinet Lekarski

🇵🇱

Rzeszow, Poland

Melita Medical

🇵🇱

Wrocław, Poland

Centralny Szpital Kliniczny Ministerstwa Spraw

🇵🇱

Warszawa, Poland

Centrum Diagnostyczno Lecznicze Barska

🇵🇱

Wloclawek, Poland

NZOZ Centrum Gastroenterologii w Wodzislawiu Slaskim

🇵🇱

Wodzislaw Slaski, Poland

Clinhouse Centrum Medyczne

🇵🇱

Zabrze, Poland

ENDOMED s.r.o.

🇸🇰

Kosice, Slovakia

Gastro LM s.r.o.

🇸🇰

Presov, Slovakia

SANTA FAMILIA Centrum Badan Profilaktyki i Leczenia

🇵🇱

Łódź, Poland

Pigeas s.r.o.

🇸🇰

Martin, Slovakia

Fakuktna Nemocnica Nitra

🇸🇰

Nitra, Slovakia

© Copyright 2025. All Rights Reserved by MedPath